Bei Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Bei Zhang has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Corina Kohler
Laboratory for Gynecological Oncology, Department of Biomedicine, Women’s Hospital, University of Basel, Hebelstrasse 20, Room 420, Basel, CH 4031, Switzerland
1 shared publication - Feng Feng Cai
Laboratory for Gynecological Oncology, Department of Biomedicine, Women’s Hospital, University of Basel, Hebelstrasse 20, Room 420, Basel, CH 4031, Switzerland
1 shared publication - Ming-Hong Wang
Tongji University
1 shared publication - Wei Jie Chen
Laboratory for Gynecological Oncology, Department of Biomedicine, Women’s Hospital, University of Basel, Hebelstrasse 20, Room 420, Basel, CH 4031, Switzerland
1 shared publication - Xiao Yan Zhong
University of Basel
1 shared publication
Latest Publications
- Open Access
- 11 July 2011
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 12 (7) , 4465-4476
Epigenetic Therapy for Breast Cancer
Both genetic and epigenetic alterations can control the progression of cancer. Genetic alterations are impossible to reverse, while epigenetic alterations are reversible. This advantage suggests that epigenetic modifications should be preferred in therapy applications. DNA methyltransferases and histone deacetylases have become the primary targets for studies in epigenetic therapy. Some DNA methylation inhibitors and histone deacetylation inhibitors are approved by the US Food and Drug Administration as anti-cancer drugs. Therefore, the uses of epigenetic targets are believed to have great potential as a lasting favorable approach in treating breast cancer.
- 11 July 2011
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 12 (7) , 4465-4476
Open AccessEpigenetic Therapy for Breast Cancer
Both genetic and epigenetic alterations can control the progression of cancer. Genetic alterations are impossible to reverse, while epigenetic alterations are reversible. This advantage suggests that epigenetic modifications should be preferred in therapy applications. DNA methyltransferases and histone deacetylases have become the primary targets for studies in epigenetic therapy. Some DNA methylation inhibitors and histone deacetylation inhibitors are approved by the US Food and Drug Administration as anti-cancer drugs. Therefore, the uses of epigenetic targets are believed to have great potential as a lasting favorable approach in treating breast cancer.